Yohta Shimada
Overview
Explore the profile of Yohta Shimada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
6427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Higuchi T, Shimada Y, Takahashi Y, Kato F, Ohashi T, Kobayashi H
Mol Genet Metab
. 2024 Jul;
143(1-2):108545.
PMID: 39068683
Anderson-Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a pathological variant of the α-galactosidase A (GLA) gene that results in deficient GLA activity. GLA deficiency leads to...
2.
Ogata J, Shimada Y, Ohashi T, Kobayashi H
Mol Genet Metab
. 2024 May;
142(3):108494.
PMID: 38820907
Background: Fabry disease (FD) is characterized by deficient activity of α-galactosidase A (GLA). Consequently, globotriaosylceramide (Gb3) accumulates in various organs, causing cardiac, renal, and cerebrovascular damage. Gene therapies for FD...
3.
Tsunogai T, Ohashi T, Shimada Y, Higuchi T, Kimura A, Watabe A, et al.
Mol Ther Methods Clin Dev
. 2022 Oct;
27:89.
PMID: 36186953
[This corrects the article DOI: 10.1016/j.omtm.2022.04.012.].
4.
Shimada Y, Ishii N, Higuchi T, Goto M, Ohashi T, Kobayashi H
Gene Ther
. 2022 Jul;
30(3-4):288-296.
PMID: 35835952
A hematopoietic stem cell (HSC) gene therapy (GT) using lentiviral vectors has attracted interest as a promising treatment approach for neuropathic lysosomal storage diseases. To proceed with the clinical development...
5.
Yanagaki M, Shirai Y, Shimada Y, Hamura R, Taniai T, Horiuchi T, et al.
Carcinogenesis
. 2022 Jul;
43(9):826-837.
PMID: 35781559
Sphingolipid metabolism plays an important role in the formation of cellular membranes and is associated with malignant potential and chemosensitivity of cancer cells. Sphingolipid degradation depends on multiple lysosomal glucosidases....
6.
Tsunogai T, Ohashi T, Shimada Y, Higuchi T, Kimura A, Watabe A, et al.
Mol Ther Methods Clin Dev
. 2022 May;
25:448-460.
PMID: 35615711
GM1-gangliosidosis is a progressive neurodegenerative glycosphingolipidosis resulting from a gene mutation causing a deficiency of the lysosomal enzyme β-galactosidase, which leads to the abnormal accumulation of GM1 ganglioside in the...
7.
Taniai T, Shirai Y, Shimada Y, Hamura R, Yanagaki M, Takada N, et al.
Cancer Sci
. 2021 Aug;
112(11):4570-4579.
PMID: 34459070
Although the inhibition of acid ceramidase (AC) is known to induce antitumor effects in various cancers, there are few reports in pancreatic cancer, and the underlying mechanisms remain unclear. Moreover,...
8.
Hamura R, Shirai Y, Shimada Y, Saito N, Taniai T, Horiuchi T, et al.
Cancer Sci
. 2021 May;
112(6):2335-2348.
PMID: 33931930
Lysosomal degradation plays a crucial role in the metabolism of biological macromolecules supplied by autophagy. The regulation of the autophagy-lysosome system, which contributes to intracellular homeostasis, chemoresistance, and tumor progression,...
9.
Klionsky D, Abdel-Aziz A, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al.
Autophagy
. 2021 Feb;
17(1):1-382.
PMID: 33634751
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our...
10.
Wada M, Shimada Y, Iizuka S, Ishii N, Hiraki H, Tachibana T, et al.
Mol Ther Methods Clin Dev
. 2020 Oct;
19:261-274.
PMID: 33102618
Mucopolysaccharidosis type II is a disease caused by organ accumulation of glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated the pathophysiology of the bone complications associated with mucopolysaccharidosis II...